智通财经网·2025-12-12 06:16Core Viewpoint - The approval of the second-generation small molecule pan-TRK inhibitor, Zoltracitinib (ICP-723), by the National Medical Products Administration (NMPA) marks a significant advancement for the treatment of adult and adolescent patients with NTRK fusion gene-related solid tumors, indicating a potential growth opportunity for the company in the oncology market [1] Company Summary - NMPA has approved Zoltracitinib for treating adult and adolescent patients aged 12 and above with solid tumors carrying NTRK fusion genes [1] - The company plans to submit a New Drug Application (NDA) for Zoltracitinib to treat pediatric patients aged 2 to 12 years soon [1] Industry Summary - NTRK fusion genes are found in over 26 types of solid tumors, with an estimated 6,500 new cases carrying NTRK fusion genes diagnosed annually in China [1] - Patients with NTRK fusion gene-related tumors typically have a short survival period, rapid disease progression, and high disability rates, highlighting an unmet clinical need due to the low prevalence of next-generation sequencing (NGS) for diagnosis [1]